Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment

BMC Palliative Care

Research

Ge-Lin Chiu¹  Yu-Yeh Chen¹  Wei-Shu Lai²  Ying-Tzu Huang³  I-Ting Liu³  Jui-Hung Tsai⁴  Peng-Chan Lin⁴  Pei-Fang Su⁵ 

[1] Department of Nursing, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University in Tainan, Tainan, Taiwan;Department of Nursing, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University in Tainan, Tainan, Taiwan;Department of Nursing, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan, Taiwan;Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan, Taiwan;Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Center for Hospice Palliative Shared Care, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Department of Statistics, National Cheng Kung University, Tainan, Taiwan;

关键词: Neuropathic pain;    Transdermal patch;    Cancer pain;    Numerical rating scale;    Analgesic;   

DOI  :  10.1186/s12904-023-01126-3

 received in 2022-02-15, accepted in 2023-01-03,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundLimited efficacy has been observed when using opioids to treat neuropathic pain. Lidocaine patches reduce neuropathic pain in postherpetic neuralgia, but their benefits for cancer-related neuropathic pain remain unclear. This study aimed to investigate a treatment for cancer-related neuropathic pain.MethodsWe conducted a prospective, open-label, single-arm study to assess the efficacy and safety of lidocaine transdermal patches in patients experiencing localized, superficial, neuropathic cancer pain. Terminal cancer patients already receiving opioid treatment participated in the 3-day study. The primary endpoint was pain intensity evaluated by the numerical rating scale (NRS). The secondary endpoints were the pain relief score and the quality of analgesic treatment.ResultsThe results showed a significant difference in the median NRS over 3 days (Kruskal–Wallis test, p < 0.0001). The median NRS pain intensity from Day 1 to Day 3 was 4.0 with 95% C.I. (3.3, 5.0), 3.0 (2.5, 3.5), and 2.6 (2.0, 3.0), respectively. The difference between the median NRS pain intensities of any 2 days was significant (Wilcoxon signed-rank test, p < 0.0001). The generalized estimating equation (GEE) estimation model showed significant differences between the NRS pain intensities on any 2 days. There was no significant difference in the pain relief score or the quality of analgesic treatment.ConclusionsIn this study, the 5% lidocaine transdermal patch reduced the NRS pain intensity in neuropathic cancer patients already receiving opioid treatment. Treatment of localized and superficial neuropathic pain caused by cancer was well tolerated and effective.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40798_2022_490_Article_IEq56.gif

40798_2022_490_Article_IEq54.gif

40798_2022_490_Article_IEq53.gif

40798_2022_490_Article_IEq510.gif

Fig. 1